Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q08334
UPID:
I10R2_HUMAN
Alternative names:
Cytokine receptor class-II member 4; Cytokine receptor family 2 member 4; Interleukin-10 receptor subunit 2
Alternative UPACC:
Q08334; Q9BUU4
Background:
Interleukin-10 receptor subunit beta, also known as Cytokine receptor class-II member 4, plays a pivotal role in immune regulation. It is a shared cell surface receptor essential for the activation of cytokines IL10, IL22, IL26, IL28, and IFNL1, facilitating the JAK/STAT signaling pathway and promoting the expression of antiviral genes.
Therapeutic significance:
Given its involvement in Inflammatory bowel disease 25, understanding the role of Interleukin-10 receptor subunit beta could open doors to potential therapeutic strategies, particularly in managing Crohn's disease and ulcerative colitis.